Sound Blade Medical Closes $16.5 Million Series A Financing to Advance the Development of Innovative Handheld Histotripsy Therapy
Summary
Funds will be used to accelerate the development and clinical validation of its pioneering technology designed to bring the benefits of precision ultrasound therapy to a wide range of patient conditions. "Histotripsy is a non-invasive, non-ionizing and non-thermal ablation technology guided by real-time imaging that uses focused ultrasound delivered from outside the body to mechanically destroy targeted tissue. Were combining a highly accomplished founding team with an investor syndicate that has built many successful Medtech companies to unlock the full promise of this platform. "Gerry Brunk, Managing Director at Lumira Ventures, commented, "Were excited to continue our long history of backing world-class medical device companies in Canada. With its roots at Dalhousie University and Nova Scotia Health, Sound Blade represents Lumiras second investment in the exciting field of histotripsy for the non-invasive treatment of important diseases.